More than 600,000 bottles of the blood pressure medication ramipril have been recalled across the United States due to potential contamination. The FDA initiated the recall after finding that the drug contained ingredients sourced from an uninspected manufacturing facility in India. While no adverse events have been reported, the contamination risk is a concern.
The recall involves bottles produced by Lupin Pharmaceuticals in three strengths: 2.5 mg, 5 mg, and 10 mg. Affected bottles, containing 90, 100, or 500 capsules, have expiration dates extending to July 2026. The FDA classified the recall as Class II, indicating a low likelihood of severe injury but acknowledging possible adverse effects.
Patients are advised to stop using the affected medication, return it to the retailer, and consult their healthcare providers for alternatives. The FDA has published a detailed list of recalled products on its website to help consumers identify affected bottles.
This recall follows similar issues with Indian-made drugs, including cancer-causing impurities in cinacalcet and contaminated eye drops linked to serious infections in 2022. The incident highlights ongoing quality control challenges in overseas manufacturing, emphasizing the need for vigilance in pharmaceutical safety.
